{"nctId":"NCT01203319","briefTitle":"The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines","startDateStruct":{"date":"2006-11"},"conditions":["Hepatitis b"],"count":1091,"armGroups":[{"label":"60mcg/1.0ml recombinant hepatitis B vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: 60mcg/1.0ml recombinant hepatitis B vaccine"]},{"label":"30mcg/1.0ml recombinant hepatitis B vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: 30mcg/1.0ml recombinant hepatitis B vaccine"]},{"label":"10mcg/1.0ml recombinant hepatitis B vaccine","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: 10mcg/1.0ml recombinant hepatitis B vaccine"]}],"interventions":[{"name":"60mcg/1.0ml recombinant hepatitis B vaccine","otherNames":[]},{"name":"30mcg/1.0ml recombinant hepatitis B vaccine","otherNames":[]},{"name":"10mcg/1.0ml recombinant hepatitis B vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\nFilter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:\n\n* Healthy subjects aged 16 and older as established by medical history and clinical examination\n* The subjects or their guardians are able to understand and sign the informed consent\n* Had never received the hepatitis B vaccines\n* Subjects who can and will comply with the requirements of the protocol\n\nRevaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:\n\n* Healthy subjects aged 16 and older as established by medical history and clinical examination\n* The subjects or their guardians are able to understand and sign the informed consent\n* After the routine administration of 10mcg hepatitis B vaccines, the peak period levels of anti-HBs is lower than 10mIU/ml\n* Subjects with temperature \\<37.1°C on axillary setting\n* Subjects who can and will comply with the requirements of the protocol\n\nExclusion Criteria:\n\nFilter period: The subjects to receive first 10mcg recombinant hepatitis B vaccines:\n\n* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine\n* Family history of seizures or progressive neurological disease\n* Family history of congenital or hereditary immunodeficiency\n* Women of pregnancy, lactation or about to be pregnant in 60 days\n* Autoimmune disease or immunodeficiency\n* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws\n* Any prior administration of administration of immunoglobulins\n\nFilter period: The subjects to receive second or/and third 10mcg recombinant hepatitis B vaccines:\n\n* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations\n* Serious adverse reactions to vaccines\n* Active infections\n* Subjects who want to quit the study\n* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives\n\nRevaccination period: The nonresponders to receive first 60mcg recombinant hepatitis B vaccines:\n\n* Qualitative test of Anti-HBs, HBsAg or Anti-HBc on serum is positive\n* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations\n* Family history of seizures or progressive neurological disease\n* Family history of congenital or hereditary immunodeficiency\n* Women of pregnancy, lactation or about to be pregnant in 60 days\n* Autoimmune disease or immunodeficiency\n* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws\n* Any prior administration of immunoglobulins, any other vaccines or experimental drugs in the last 7days\n* Any active infections and received any antibiotic or anti-virus treatments in the last 7 days\n* Had a fever in the last 3 days, with temperature ≥37.1°C\n* Participate in another clinical trials\n* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives\n\nRevaccination period: The nonresponders to receive second or/and third 60mcg recombinant hepatitis B vaccines:\n\n* Any reaction or hypersensitivity to the recombinant hepatitis B vaccines after the vaccinations\n* Serious adverse reactions to vaccines\n* Active infections\n* Subjects who want to quit the study\n* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders","description":"Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after second vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"394","spread":null},{"groupId":"OG001","value":"371","spread":null},{"groupId":"OG002","value":"180","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders","description":"Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after third vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null},{"groupId":"OG001","value":"394","spread":null},{"groupId":"OG002","value":"187","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of Recombinant Hepatitis B Vaccines in Nonresponders","description":"Quantitative detection of anti-HBs using ratio-immunity method on serum obtained one month after first vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"331","spread":null},{"groupId":"OG002","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"the Safety of Recombinant Hepatitis B Vaccines in Nonresponders","description":"assessment of the local and systemic adverse reaction within the first 30 days after first vaccination","classes":[]},{"type":"SECONDARY","title":"the Safety of Recombinant Hepatitis B Vaccines in Nonresponders","description":"assessment of the local and systemic adverse reaction within the first 30 days after second vaccination","classes":[]},{"type":"SECONDARY","title":"the Safety of Recombinant Hepatitis B Vaccines in Nonresponders","description":"assessment of the local and systemic adverse reaction within the first 30 days after third vaccination","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":434},"commonTop":[]}}}